First US patient enrolled in e-OPRA trial combining osseointegration, nerve rerouting, and implanted sensory feedback

The first patient in a US clinical development program for the e-OPRA Implant System has undergone surgery at Northwestern Memorial Hospital. It is the first US implantation of the device, which combines four prosthetic technologies in a single procedure: bone-anchored attachment, targeted muscle reinnervation, implanted muscle sensors with pattern-recognition control, and nerve-based sensory feedback.

The program is led by the Regenstein Foundation Center for Bionic Medicine at Shirley Ryan AbilityLab, in collaboration with Northwestern Medicine and the University of Chicago. Eight patients will be enrolled. The study, funded by an $8.7 million award from the National Institute of Neurological Disorders and Stroke, is expected to conclude in 2030. Results will be made publicly available at that point. The procedure was performed under a US Food and Drug Administration investigational device exemption.

The four components

The base technology is osseointegration. Instead of suspending the residual limb inside a socket, a titanium implant anchors directly into the bone of the residual limb. Bone grows into the implant over several months. The prosthetic limb then attaches to a percutaneous abutment rather than wrapping around the limb surface. Osseointegration as a standalone procedure has been available at a limited number of US centers for several years. This site has a fuller explainer of how it works and who is typically a candidate.

What the clinical program adds is three modifications performed during the same surgery.

Targeted muscle reinnervation (TMR) reroutes residual nerves, those that once ran to the amputated portion of the limb, to new muscle targets in the residual limb. Those muscles then carry signals that would otherwise have no destination, and they become additional sites a prosthetic controller can read. TMR has been used as a standalone procedure and in combination with surface-electrode myoelectric systems; the e-OPRA study combines it with an implanted sensing interface instead.

The pattern-recognition component uses sensors implanted inside the reinnervated muscles. Surface electrodes, the standard for myoelectric control, pick up signals through skin and tissue, which introduces noise and limits how many distinct movement commands the system can reliably decode. Implanted sensors sit closer to the source. A pattern-recognition algorithm reads those signals and infers intended movement. In principle this should support more reliable multi-motion control than conventional two-site surface setups provide, though the study’s purpose is to test whether that holds in practice.

The fourth component is sensory feedback. Electrodes placed around the residual nerve deliver electrical pulses that the nervous system interprets as sensation from the prosthesis. Current implementations convey something more like pressure presence and contact location than fine-grained tactile detail. The goal is to close the loop: the user sends a movement command and receives a signal about what the limb is doing.

What the study is actually testing

The researchers describe the program as intended to “inform the future development of implantable intelligent bionics.” Eight patients is a small cohort, and this is not a pivotal trial aimed at US regulatory approval. The four components have been developed and studied individually; combining them into one surgical procedure and one integrated system is the thing the study is designed to evaluate. Whether the combination produces better outcomes than any subset would alone is still an open question.

No timeline for commercial availability of the combined system in the United States exists.

Rickard Brånemark, Integrum’s chief medical and scientific officer, said the e-OPRA program “builds on the value of our bone-anchored implants and addresses an area of growing interest: connecting the body to the prosthesis through skeletal anchoring, the decoding of muscle signals and restored sensory feedback.” The Brånemark name traces to the original development of osseointegration in dental medicine.

What this means for people considering osseointegration

If you have been looking into osseointegration, this study does not change what is available to you now. The e-OPRA combination is an investigational device. The trial is enrolling at Shirley Ryan AbilityLab and is not a path to clinical access for patients outside the study.

What the trial does is systematically test whether all four components can be safely implanted together and whether the combination produces outcomes that justify its added complexity. That data will not exist until at least 2030.

The study is worth following for anyone interested in where implantable prosthetic control is heading. It is not a near-term clinical development for most readers.

---

This article describes an investigational clinical research program. The e-OPRA Implant System is not approved for commercial use in the United States. Nothing here constitutes advice about whether any procedure or device is appropriate for you. Consult qualified medical professionals for decisions about your care.